Skip to main content

Table 3 The classification by chemotherapy regimens

From: Pharmacoeconomic effect of compliance with pharmacist’s intervention based on cancer chemotherapy regimens: a cohort study

Chemotherapy regimen

Total n = 96

Complying group n = 58

Non-complying group n = 38

5-flourouracil

1

1

0

ABVD

2

0

2

AC

7

6

1

Bendamustine

3

0

3

B-mab+CBDCA+PAC

1

1

0

B-mab+mFOLFOX6

3

2

1

CBDCA+GEM

2

2

0

CBDCA+VP16

2

2

0

CHOP

5

1

4

DeVIC

2

1

1

DOC

2

0

2

DOXIL

2

2

0

GC

1

1

0

GEM

12

12

2

High dose-AraC

2

0

2

Hign dose MTX

2

0

2

Irinotecan

2

2

0

Pemetrexed + CBDCA

3

3

0

Pemetrexed

1

1

0

PAC+GEM

2

2

0

R-CHOP

3

0

3

Rituximab

1

1

0

R-THPCOP

10

4

6

S1+DOC

2

2

0

S1+CDDP

1

1

0

S1+GEM

8

6

2

SOX

4

1

3

THPCOP

2

0

2

VNR + HER

1

0

1

CBDCA+PAC

1

1

0

Weekly PAC

1

1

0

Weekly PAC+ HER

2

1

1

  1. ABVD: doxorubicin+ bleomycin+ vincristine+ dacarbazine, B-mab: bevacizumab, CBDCA: carboplatin, PAC: paclitaxel mFOLFOX 6: 5-fluorouracil+ levofolinate+ oxaliplatin, DOC: docetaxel, GEM: gemcitabine, VP16: etoposide, CHOP: cyclophosphamide+ doxorubicin+ vincristine + predonizorne, DeVIC: carboplatin+etoposide+ifosfamide, GC: emcitabine+ cisplatin, AraC: cytarabine, MTX: methotrexate, R: rituximab, THPCOP: rituximap+cyclophosphamide+pirarubicin+vincristine + Predonizorne, S1: Tegafur+ gimeracil+ oteracil, CDDP: cisplatin, SOX: S1+ oxaliplaton, VNR: vinorelbine, HER: trastuzumab.